Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Xilio Therapeutics (XLO) Return on Capital Employed (2024 - 2026)

Xilio Therapeutics' Return on Capital Employed history spans 3 years, with the latest figure at 36.38% for Q1 2026.

  • On a quarterly basis, Return on Capital Employed rose 10685.0% to 36.38% in Q1 2026 year-over-year; TTM through Mar 2026 was 36.38%, a 10685.0% increase, with the full-year FY2025 number at 74.16%, up 8222.0% from a year prior.
  • Return on Capital Employed hit 36.38% in Q1 2026 for Xilio Therapeutics, up from 47.75% in the prior quarter.
  • Over the last five years, Return on Capital Employed for XLO hit a ceiling of 36.38% in Q1 2026 and a floor of 143.23% in Q1 2025.
  • Historically, Return on Capital Employed has averaged 83.87% across 3 years, with a median of 71.51% in 2025.
  • Biggest five-year swings in Return on Capital Employed: surged 8509bps in 2025 and later skyrocketed 10685bps in 2026.
  • Tracing XLO's Return on Capital Employed over 3 years: stood at 132.84% in 2024, then skyrocketed by 64bps to 47.75% in 2025, then increased by 24bps to 36.38% in 2026.
  • Business Quant data shows Return on Capital Employed for XLO at 36.38% in Q1 2026, 47.75% in Q4 2025, and 56.59% in Q3 2025.